Zimmer Biomet Holdings (ZBH) 10-K Summary — Year Ended Dec 31, 2025
Zimmer Biomet Holdings, Inc. filed its annual report for the most recent fiscal year. The filing describes the company's business, risk factors, financial condition, and liquidity position.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Zimmer Biomet Holdings, Inc. filed its annual report for the most recent fiscal year. The filing describes the company's business, risk factors, financial condition, and liquidity position.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$8.2B
Revenue reported for the fiscal year.
Operating income
$1.1B
Income from operations reported for the year.
Net income
$705.1M
Net income reported for the year.
Operating cash flow
$1.7B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $6.9B | +1.6% |
| Dec 31, 2023 | $7.4B | +6.5% |
| Dec 31, 2024 | $7.7B | +3.8% |
| Dec 31, 2025 | $8.2B | +7.2% |
Business overview
The company operates in the musculoskeletal healthcare industry, focusing on products and solutions for joint replacement, sports medicine, and related surgical procedures. The business overview section outlines its market presence and product portfolio.
Financial performance
Revenue increased compared to the prior year, driven by higher net sales. Operating income and net income also rose, while operating cash flow improved due to favorable timing of accounts payable and lower bonus and restructuring payments.
Material risks
The filing identifies risks including potential adverse effects from forward-looking statements not materializing, uncertainties in securing additional financing on favorable terms, and costs related to acquisitions and tariffs. Readers are cautioned that actual results may differ materially from projections.
Liquidity and capital
The company believes its cash flows from operations, cash on hand, and available borrowings under revolving credit facilities are sufficient for liquidity needs for at least the next twelve months. It also has access to additional borrowing capacity under two credit agreements.
What to watch
Monitor the company's ability to integrate recent acquisitions and manage related costs, as well as any changes in tariff exposure.